Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.

Publication Type:

Journal Article


Pharmacotherapy, Volume 32, Issue 1, p.7-19 (2012)


2012, Center-Authored Paper, Clinical Research Division, March 2012, Public Health Sciences Division


To determine the impact of primary prophylactic colony-stimulating factor (CSF) use on febrile neutropenia in a large patient population receiving contemporary chemotherapy regimens to treat breast cancer, colorectal cancer, or non-small cell lung cancer (NSCLC).